Evidence map›Paper›PMID 36600560›Full record

ArticleJournal for immunotherapy of cancer2022

Development of

Arjan Kol, Xiaoyu Fan, Marta A Wazynska, Sander M J van Duijnhoven, Danique Giesen, Annechien Plat, Hans Van Eenennaam, Philip H Elsinga, Hans W Nijman, Marco de Bruyn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Development of [EJNMMI research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Arjan Kol *Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Xiaoyu Fan *Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0001-9563-4732
Marta A WazynskaObstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Sander M J van DuijnhovenAduro Biotech Europe, Oss, The Netherlands.
Danique GiesenNuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Annechien PlatObstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Hans Van EenennaamAduro Biotech Europe, Oss, The Netherlands.
Philip H ElsingaNuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Hans W NijmanObstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Marco de BruynObstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands m.de.bruyn@umcg.nl.ORCID 0000-0001-9819-9131
University Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is significantly increased during successful immunotherapy across human malignancies. In this study, we describe the generation and zirconium-89 ( EXPERIMENTAL

designFirst, to determine the feasibility of anti-CD103 immuno-PET to visualize CD103-positive cells at physiologically and clinically relevant target densities, we developed an

results

conclusionCD103 immuno-PET tracers visualize CD103 T cells at relevant densities and are suitable for future non-invasive assessment of cancer reactive T cell infiltration.

Indexed as

NeoplasmsPositron-Emission TomographyAnimalsAntibodies, MonoclonalCHO CellsCricetinaeCricetulusHumansMiceMice, Inbred C57BLMice, NudeTissue DistributionAntibodies, Monoclonalbiomarkers, tumorlymphocytes, tumor-infiltrating

Identifiers

PMID36600560
PMCPMC9723959
OpenAlexW4310728354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.